Mucosal surfaces of the gut are colonized by large numbers of heterogeneous bacteria that contribute to intestinal health and disease. In genetically susceptible individuals, a 'pathogenic community' may arise, whereby abnormal gut flora contributes to alterations in the mucosa and local immune system leading to gastrointestinal disease. These diseases include enteric infections, such as Clostridium difficile infection, small intestinal bacterial overgrowth, functional gastrointestinal disorders (including IBS), IBD and colorectal cancer. Prebiotics, probiotics and synbiotics (a combination of prebiotics and probiotics) have the capacity to reverse pathologic changes in gut flora and local immunity.
16s rRNA gene, a highly conserved component, is the most widely used gene marker for genus and species identification and taxonomic significance in bacteria and archaea. The estimated substitution rate for hypervariable regions is approximately 7000 times higher than the highly conserved ones, which contains abundant taxonomic information based on these genetic differences. Therefore, the 16S gene amplicons obtained from PCR can be used to deduce taxonomic identifications based upon bioinformatics alignments.
CD Genomics can help you identify the bacteria in the lumen of the gut and predict the risk of bowel related diseases. Then improving diet habits, adjusting lifestyle, intaking of functional food and other ways to normalize the composition of intestinal flora to prevent the diseases occur.
Sample Requirements
|
|
Sequencing
|
|
Bioinformatics Analysis We provide customized bioinformatics analysis including:
|
CD Genomics provides the accurate and cost-effective 16S amplicon sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for 16S amplicon sequencing is outlined below.
For more information about the intestinal flora detection or need other amplification requirements, please contact us.